Skip to main content
logo
Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
59.65
+0.64 (1.08%)
Sep 3, 2026, 4:00 PM EDT - Market closed

Enliven Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
4,3719141,099570--
Market Cap Growth
264.00%-16.86%92.74%---
Enterprise Value
3,477437808307--
Last Close Price
59.6515.4022.5013.84--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
4.881.993.552.32--
P/TBV Ratio
4.881.993.552.32--

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.00-0.000.010.00
Net Debt / Equity Ratio
-1.00-1.01-1.01-1.03-1.03-1.03
Net Debt / EBITDA Ratio
7.193.873.013.091.944.46
Net Debt / FCF Ratio
13.336.564.284.122.295.69
Quick Ratio
63.2127.9219.709.787.7819.13
Current Ratio
64.0728.6619.9910.288.0019.24
Return on Equity (ROE)
-15.31%-26.95%-32.04%-44.90%-41.90%-20.94%
Return on Assets (ROA)
-11.00%-18.65%-21.87%-28.94%-24.66%-12.67%
Return on Capital Employed (ROCE)
-13.90%-26.00%-33.70%-33.40%-52.70%-23.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-2.42%-11.35%-8.10%-12.55%--
FCF Yield
-1.53%-7.71%-6.66%-10.77%--
Buyback Yield / Dilution
-26.53%-20.38%-32.43%-1037.74%60.02%-56.70%
SEC Filings: 10-K · 10-Q